Summary:
The purpose of this study is to determine if treatment with dempedoic acid (ETC-1002) versus placebo decreases the risk of cardiovascular events in patients who are statin intolerant
Qualified Participants Must:
Age between 18 and 85 years
History of, or at high risk for, cardiovascular disease (CVD) including coronary artery disease, symptomatic peripheral arterial disease, cerebrovascular atherosclerotic disease, or at high risk for a cardiovascular event
Patient reported history of statin intolerance
Men and nonpregnant, nolactating women
Fasting blood LDL-cholesterol greater than 100 at screening
Qualified Participants May Receive:
Compensation for time and travel